Quantitative Concept – Page 64

J&J Scores First-Line Approval for Rybrevant Combination in Lung Cancer with EGFR Exon 20 Mutations

2 years ago talkbio0Tagged amivantamab-vmjw, Approved, carboplatin-pemetrexed chemotherapy, Disease Progression, EGFR Exon 20, first-line, Insertion Mutation, Johnson and Johnson, Mortality Risk, Non-Small Cell Lung Carcinoma, Objective Response Rate, ORR, Progression-Free Survival, Reduced, Rybrevant, United States Food and Drug Administration

Johnson & Johnson, Rybrevant (amivantamab-vmjw), FDA Approval, First-Line Treatment, Non-Small Cell Lung Cancer (NSCLC), EGFR Exon 20 Insertion Mutations, Carboplatin-Pemetrexed Chemotherapy, Phase 3 PAPILLON Study, Reduced Disease Progression or Mortality Risk, Improved Objective Response Rate (ORR) and Progression-Free Survival (PFS)

Gilead Sciences Receives $210 Million Venture Capital Funding to Expand Trodelvy’s Application in Non-Small Cell Lung Cancer (NSCLC)

2 years ago talkbio0Tagged Application procedure, Capital, Non-Small Cell Lung Carcinoma, Trodelvy, Trodelvy's

Non-Small Cell Lung Carcinoma, Capital, Trodelvy, Trodelvy’s, Application procedure

Kenai Therapeutics Secures $82M Series A to Develop Off-the-Shelf Neuron Replacement Cell Therapy for Parkinson’s

2 years ago talkbio0Tagged RNDP-001

RNDP-001

Sandoz Pays $265 Million to Resolve Partial Antitrust Claims in Price Fixing Lawsuits

2 years ago talkbio0Tagged Litigation, sandoz, Settlement and Resettlement

sandoz, Settlement and Resettlement, Litigation

Blooming Potential: BlossomHill Secures $100M Series B Funding for Small Molecule Cancer & Autoimmune Treatments

2 years ago talkbio0

– BlossomHill Therapeutics, a biotech focusing on small-molecule drug design, has raised $100 million in a Series B financing round. – Led by Colt Ventures, the funding includes investors such as OrbiMed, Cormorant Asset Management, Vivo Capital, Hercules BioVentures Partners, and others. – Total capital raised by BlossomHill reaches $173 million after this round. – […]